Lean Body Mass as a Clinical Outcome in Multicentric Castleman’s Disease

September 3, 2014
Michael Sawyer, MD

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.

Clinical Pearls

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.

  • Lean body mass is an important clinical outcome because it appears to be related to frailty in other literatures.
  • The hope is to eventually study the relationship between fatigue, function, and lean body mass in patients on siltuximab.